When Groups Are Forgotten.

Area of Science:

• Pediatric Pharmacology
• Drug Development
• Clinical Trials

Background:

• The Pharmacy and Therapeutics Committee reviews medications, noting a significant gap in FDA-approved indications for pediatric populations.
• Child and adolescent psychiatrists and pediatricians are often the sole representatives for pediatric interests in these committees.
• Many medications are developed and approved solely for adult use, despite potential relevance to pediatric conditions.

Purpose of the Study:

• To highlight the disparity in medication development and FDA approval for pediatric versus adult populations.
• To advocate for the inclusion of children in crucial drug trials and the subsequent approval processes.
• To emphasize the need to address the oversight of pediatric patients in pharmaceutical research.

Main Methods:

• Analysis of medication review processes within a Pharmacy and Therapeutics Committee.
• Observation of the rationale behind the lack of pediatric-specific drug indications (i.e., absence of pediatric trials).
• Qualitative assessment of the impact of overlooking children in drug development decisions.

Main Results:

• A substantial number of medications lack FDA-approved indications for children, even when potentially beneficial.
• The primary reason cited for this deficit is the exclusion of children from clinical trials during drug development.
• This oversight results in children being potentially denied access to necessary treatments.

Conclusions:

• Children are frequently overlooked in the process of medication development and approval.
• Child and adolescent psychiatrists must act as advocates to ensure pediatric needs are met.
• There is a critical need for broader inclusion of underrepresented groups, including children, in medical research.